Paricalcitol Versus Calcitrol in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Dependent Patients
Abstract
Objective: To compare the efficacy of paricalcitol with calcitriol for treatment of secondary hyperparathyroidism in dialysis patients.Methods
This Randomized Controlled Trial (RCT) was carried out in Department of Nephrology, FMU & Allied th th Hospital, Faisalabad in six months period from 13 November 2023 to 12 May 2024. A total of 100 dialysis dependent patients having secondary hyperparathyroidism were included and divided into two groups. Patients in Group A received paricalcitol at a dose of 1µg/day for a period of 12 weeks. Patients in Group B took calcitriol at a dosage of 0.5 micrograms per day for a period of 12 weeks. The effectiveness was evaluated after a treatment period of twelve weeks.Results
The mean age of patients in group A was 48.48 ± 6.57 years and in group B was 48.0 ± 8.01 years. Out of these 100 patients, 52 (52.0%) were males and 48 (48.0%) were females. Efficacy in Paricalcitol was seen in 41 (82.0%) patients and in Calcitriol was seen in 29 (58.0%) patients with p-value of 0088 which is statistically significant.Conclusion
This study concluded that paricalcitol is better than calcitriol for treatment of secondary hyperparathyroidism in dialysis patients.Keywords:
Dialysis, Secondary Hyperparathyroidism, Paricalcitol.Published
2025/08/23
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com